Howard H. Pien

Président chez Reckitt Benckiser Pharmaceuticals, Inc.

Profil

Howard H.
Pien is currently the Chairman at Reckitt Benckiser Pharmaceuticals, Inc. and the Director at Sapience Therapeutics, Inc. He previously held positions such as Chairman, President & Chief Executive Officer at Chiron Corp., Chairman, President & Chief Executive Officer at Medarex, Inc., Non-Executive Chairman at Vanda Pharmaceuticals, Inc., Chairman at Indivior PLC, Non-Executive Chairman at Juno Therapeutics, Inc., Independent Director at ImmunoGen, Inc., Lead Independent Director at Shire ViroPharma, Inc., and President-North American Pharmaceuticals at Smithkline Beecham Plc.
He has also served as a Director at various organizations including Biotechnology Innovation Organization, Ikaria, Inc., Bellerophon Therapeutics, Inc., Talon Therapeutics, Inc., UCSF Benioff Children's Hospital Oakland, The Fox Chase Cancer Center, Pharmaceutical Research & Manufacturers of America, Talon International, Inc., Arresto BioSciences, Inc., SAGE Therapeutics, Inc., Ophirex, Inc., and Abbott Laboratories.
Mr. Pien has an MBA from Carnegie Mellon University and an undergraduate degree from Massachusetts Institute of Technology.

Postes actifs de Howard H. Pien

Sociétés	Poste	Début
Reckitt Benckiser Pharmaceuticals, Inc.	Président	-
Sapience Therapeutics, Inc.	Directeur/Membre du Conseil	01/01/2020

Anciens postes connus de Howard H. Pien

Sociétés	Poste	Fin
Indivior Ltd.	Président	15/06/2020
JUNO THERAPEUTICS INC	Président	06/03/2018
IMMUNOGEN, INC.	Directeur/Membre du Conseil	19/01/2018
SAGE THERAPEUTICS, INC.	Directeur/Membre du Conseil	07/06/2017
VANDA PHARMACEUTICALS INC.	Président	01/01/2016